{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4"},{"groupId":"OG001","value":"12.6"}]}],"title":"Excellent (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"28.8"}]}],"title":"Good (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.2"},{"groupId":"OG001","value":"30.6"}]}],"title":"Acceptable (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"},{"groupId":"OG001","value":"12.6"}]}],"title":"Slight (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"15.3"}]}],"title":"Poor (Core) [N=113, 111]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"17.9"}]}],"title":"Excellent (24 weeks) [N=87, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"44.9"}]}],"title":"Good (24 weeks) [N=87, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7"},{"groupId":"OG001","value":"25.6"}]}],"title":"Acceptable (24 weeks) [N=87, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"9.0"}]}],"title":"Slight (24 weeks) [N=87, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"2.6"}]}],"title":"Poor (24 weeks) [N=87, 78]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Patients made a global assessment of response to treatment using a 5-point Likert scale: Excellent, good, acceptable, slight, poor. Percentage of participants in each category for both core and extension periods were measured.","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.","reportingStatus":"POSTED","timeFrame":"72 hours post-dose (randomization), 72 hours post-dose for the last post-baseline flare (during 24 weeks overall)","title":"Patient's Global Assessment of Response to Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}